Yahoo Finance • 3 days ago
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws... Full story
Yahoo Finance • 10 days ago
Iovance Biotherapeutics(NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares... Full story
Yahoo Finance • 10 days ago
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven... Full story
Yahoo Finance • 10 days ago
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrati... Full story
Yahoo Finance • last month
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue Guidance of $450M-$4... Full story
Yahoo Finance • last month
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story
Yahoo Finance • 2 months ago
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)... Full story
Yahoo Finance • 2 months ago
If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the biopharmaceutical industry has you covered. Hardly a week goes by without clinical trial results or a regulatory decision that pr... Full story
Yahoo Finance • 2 months ago
We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s... Full story
Yahoo Finance • 7 months ago
Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs that have revenue and a clear path to gener... Full story
Yahoo Finance • 10 months ago
Iovance Biotherapeutics, Inc. Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65... Full story
Yahoo Finance • 11 months ago
Iovance Biotherapeutics(NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk resp... Full story
Yahoo Finance • 11 months ago
They're often grouped together, but not all growth stocks are the same. Indeed, they're each dramatically different in terms of risk, potential, and longevity. One's not inherently as good as another. With that as the backdrop, here's a c... Full story
Yahoo Finance • 11 months ago
It's been a tough past three years for biotech stocks. Although the COVID-19 pandemic sparked bullish interest in the industry, this interest has waned since the contagion began winding down. Between late 2021 and now, the Nasdaq Biotechno... Full story
Yahoo Finance • last year
Some investors are attracted to small biotech stocks because of their potential for explosive returns. It's not uncommon for these stocks to go parabolic after positive news is announced. That's exactly what happened to Iovance Biotherape... Full story
Yahoo Finance • last year
With shares of Iovance Biotherapeutics (NASDAQ: IOVA) soaring by 175% in the last three months, Wells Fargo analyst Yanan Zhu thinks they could still go as much as 47% higher. In fact, on Feb. 20, the analyst raised his price target for th... Full story
Yahoo Finance • last year
In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story
Yahoo Finance • last year
Shares of Iovance Biotherapeutics(NASDAQ: IOVA) had skyrocketed by 33.8% as of 10:39 a.m. ET Tuesday. The huge gain came after the company announced on Friday that the Food and Drug Administration (FDA) had granted accelerated approval for... Full story
Yahoo Finance • last year
The FDA places a clinical hold on Iovance’s trial of a lung cancer therapy after the company reports a death potentially related to the treatment. Continue reading... Full story
Yahoo Finance • last year
It isn't over yet, but 2023 has given Wall Street a lot more to be excited about than 2022 did. Signs of a soft landing for the U.S. economy have pushed the S&P 500 index up nearly 20% this year. The benchmark index is up sharply this yea... Full story